PharmCo III ApS: Financial statements 2025
CVR: 41103647
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
PharmCo III ApS (CVR 41103647) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK -33,000 and a net result of DKK 18,532,000 compared with DKK 13,877,698 the year before. Equity in the 2025 report amounted to DKK 100,696,000. The solvency ratio was 99.7%.
- Revenue
- DKK 0
- Gross Profit
- DKK -33,000
- Profit/Loss
- DKK 18,532,000
- Equity
- DKK 100,696,000
- Total Assets
- DKK 100,992,000
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | 0 | -33 t. | 18.5 mio. | 100.7 mio. | 0 |
| 2024 | 0 | -31 t. | 13.9 mio. | 75.4 mio. | - |
| 2023 | - | -29 t. | 11.1 mio. | 61.4 mio. | - |
| 2022 | - | -27 t. | 12.1 mio. | 50.6 mio. | - |
| 2021 | 0 | -26 t. | 20.5 mio. | 39 mio. | - |
Official annual report
How creditworthy is PharmCo III ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
PharmCo III ApS has published its annual report for 2024. Revenue came to DKK 0, and the net result was DKK 13,877,698.
About PharmCo III ApS
PharmCo III ApS is a Danish company of the type Anpartsselskab based in Vojens, founded in 2020. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of Eli Wallin. The company is owned by Eli Wallin. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK -33,000 and a net result of DKK 18,532,000 compared with DKK 13,877,698 the year before. Equity in the 2025 report amounted to DKK 100,696,000.